Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib + olaparib after progression on PARP inhibitor in ovarian cancer
2017-001192-23Phase 2Completed
- Sponsor
- University Health Network
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cediranib and olaparib in ovarian cancer, sponsored by University Health Network. Primary endpoint: Efficacy of cediranib + olaparib after progression on PARP inhibitor. Started Jul 2017; status: completed.
02
Drugs
cediranibolaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2017-001192-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001192-23.